ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market
The National Allied Procurement Office has issued an initial notification upon the completion of Round...
Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...
Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its...
Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results
China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...
Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment
The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...
Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope
Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced...
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...
CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health
China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the...
ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its...
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of...
Pfizer Partners with HCRC to Support ‘Healthy China’ Initiative
US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health...
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD...
Astellas Pharma Executive Arrested in China on Spying Allegations
A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO:...
China’s NHSA Introduces Tiered Pricing for COVID-19 Therapies: A, B, and C Categories
The National Healthcare Security Administration (NHSA) has issued a Notification concerning the improvement of the...
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced...
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III...